Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genetically Encoded Sensors Determine Intracellular GTP Levels

By LabMedica International staff writers
Posted on 28 Sep 2017
A new class of genetically encoded sensors is able to rapidly detect changes in GTP (guanosine-5'-triphosphate) levels in living cells.

Although GTP plays an essential role in multiple cellular processes, including protein synthesis, cytoskeleton maintenance and function, nuclear and intracellular transport, and intracellular signaling tools for quantitative evaluation of GTP levels in live cells have not been available.

To fill this gap, investigators at the Roswell Park Cancer Institute (Buffalo, NY, USA) developed and characterized genetically encoded GTP sensors, which they constructed by inserting a circularly permuted yellow fluorescent protein (cpYFP) into a region of the bacterial G protein, FeoB. More...
FeOB is a ferrous iron uptake system, which belongs to the Ferrous Iron Uptake (FeoB) transporter family that undergoes a GTP-driven conformational change.

The investigators reported in the September 4, 2017, online edition of the journal Nature Methods that GTP binding to these sensors resulted in a ratiometric change in their fluorescence, thereby providing an internally normalized response to changes in GTP levels while minimally perturbing those levels. Mutations introduced into FeoB to alter its affinity for GTP created a series of sensors with a wide dynamic range. In mammalian cells the sensors showed consistent changes in ratiometric signal upon depletion or restoration of GTP pools.

The investigators stated that their results showed that these GTP evaluators (GEVALs) were suitable for detection of spatiotemporal changes in GTP levels in living cells and for high-throughput screening of molecules that modulate GTP levels.

“Our sensors represent a new and unique tool for assessing changes in GTP levels in cell populations and individual cells, which may in turn point the way to effective strategies for suppressing or even preventing tumor growth,” said senior author Dr. Mikhail Nikiforov, professor of oncology in the department of cell stress biology at Roswell Park Cancer Institute. “This is an early finding that will have to be further developed through additional research, but it suggests opportunities for developing therapies that interfere with GTP metabolism by targeting key enzymes - perhaps existing therapies as well as new drugs yet to be developed.”

Related Links:
Roswell Park Cancer Institute


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.